medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2006, Number 03

<< Back Next >>

Ginecol Obstet Mex 2006; 74 (03)

Oral or trandsdermal hormone replacement therapy reduces interleukine-6 levels

Saucedo GR, Basurto AL, Rico RG, Galván RE, Zárate TA

Language: Spanish
References: 10
Page: 133-138
PDF size: 241.08 Kb.


ABSTRACT

Objective: To compare the effect of oral and transdermal estrogen replacement therapy (ET) on circulating interleukin-6 (IL-6) in postmenopausal women.
Patients and method: Prospective open trial study in 55 healthy hysterectomized postmenopausal women with a mean age of 52 years. Twenty-seven women received oral conjugated equine estrogens (0.625 mg daily) and the remaining 28 received transdermal estrogen replacement therapy (50 µg/day) during 6 months. At baseline both groups were similar as to age, body weight, and body mass index as well as serum levels of LH, FSH, 17-Β estradiol (E2) and IL-6.
Results: Baseline elevated IL-6 levels decreased significantly (p‹<0.05) after both oral and transdermal estrogen replacement therapy; this decrement showed no difference between the two groups. After the follow-up there were no differences in body weight and body mass index between groups; however, in the oral group there was a trend to increment this parameters. Serum levels of E2 and IL-6 were negatively correlated in the two groups and IL-6 was positively correlated with body mass index in untreated women and this correlation was the same in women with estrogen replacement therapy.
Conclusions: The decrement of IL-6 after estrogen replacement therapy was similar for both routes of administration; in addition IL-6 had a negative correlation with E2 and a positive correlation with body mass index.


REFERENCES

  1. Toth MJ, Tchernof A, Sites CK, Poehlman ET. Effect of menopausal status on body composition and abdominal fat distribution. Int J Obes Relat Metab Disord 2000;24:226-31.

  2. Pittas AG, Joseph NA, Greenberg AS. Adipocytokines and insulin resistance. J Clin Endocrinol Metab 2003;89:447-52.

  3. Davison S, Davis SR. New markers for cardiovascular disease risk in women: Impact of endogenous estrogen status and exogenous postmenopausal hormone therapy. J Clin Endocrinol Metab 2003;88:2470-8.

  4. O’Sullivan AJ, Crampton LJ, Freund J, Ho KK. The route of estrogen replacement therapy confers divergent effects on substrate oxidation and body composition in postmenopausal women. J Clin Invest 1998;102:1035-40.

  5. Kristensen K, Pedersen SB, Vestergaard P, Mosekilde L, Richelsen B. Hormone replacement therapy affects body composition and leptin differently in obese and non-obese women. J Endocrinol 1999;163:55-62.

  6. Basurto L, Saucedo R, Ochoa R, Hernandez M, Zárate A. La terapia de reemplazo hormonal con estradiol transdérmico disminuye los niveles de insulina-cortisol y lipoproteinas en mujeres posmenopáusicas. Ginecol Obstet Mex 2002;70:491-5.

  7. Stein B, Yang MX. Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-kappa B and C/EBP beta. Mol Cell Biol 1995;15:4971-9.

  8. Straub RH, Hense HW, Andus T, et al. Hormone replacement therapy and interrelation between serum interleukin-6 and body mass index in postmenopausal women: A population-based study. J Clin Endocrinol Metab 2000;85:1340-4.

  9. Saucedo R, Rico G, Basurto L, Ochoa R, Zárate A. Transdermal estradiol in menopausal women depresses interleukin-6 without affecting other markers of immune response. Gynecol Obstet Invest 2002;53:114-7.

  10. Zegura B, Keber I, Sebestjen M, Koening W. Double blind, randomized study of estradiol replacement therapy on markers of inflammation, coagulation and fibrinolysis. Atherosclerosis 2003;168:123-9.




2020     |     www.medigraphic.com